What is continuous glucose monitoring?

Continuous glucose monitors are sensor-based systems that continuously provide glucose readings day and night, without the need for fingersticks*.

A man giving flowers to a woman while she wears a CGM sensor
A man giving flowers to a woman while she wears a CGM sensor
A man giving flowers to a woman while she wears a CGM sensor
Two older men laughing while playing dominos while one man is wearing a CGM sensor

How CGM can benefit you

You may be familiar with blood glucose monitoring (BGM), which uses fingersticks to give you a snapshot of your glucose levels. In contrast, continuous glucose monitoring (CGM) gives you a complete picture of your glucose levels and provides you with trends, so you can make more informed diabetes management decisions1-3.

Check your glucose with no fingersticks* needed

Uncover hidden glucose patterns for a complete picture of where your glucose has been and where it’s going‡4

Improve your overall glucose control§II5-12, lower your A1c§II8,9, and spend less time in hypoglycemia§II5,6

Painless to apply and easy to wear‡5,13

Learn how CGM readings differ from BGM readings

How continuous glucose monitoring works with the FreeStyle Libre CGM systems

Sensor collects data

The FreeStyle Libre CGM sensors are small, unobtrusive, and easily applied§5,13 to the back of your upper arm. The sensor continuously measures and stores glucose readings when worn on your body1-3.

Glucose readings are displayed on your smartphone¶#**

The sensor sends your data to a device¶#**††, where you can view your glucose readings, reports, and trends1-3 anytime‡‡, anywhere§§.

Content Image

Discover the CGMs designed with you in mind

The FreeStyle Libre systems are the #1 CGM prescribed in the USIIII

The most affordable 

The most affordable CGM systems, even without insurance coverage¶¶13.

FDA-cleared for ages 4 & up 

Most of our CGM systems are FDA-cleared for adults and children with diabetes, ages 4 years and above1,2.

Glucose readings at your fingertips 

With the FreeStyle Libre 2 and 3 apps¶#, you can share††## and monitor*** your glucose levels and trends.

14-day accuracy 

Most of our CGMs have unsurpassed 14-day accuracy1,2 for adults and children.

Optional, real-time glucose alarms

With the FreeStyle 2 and 3 apps¶#, get real-time glucose alarms†††‡‡‡ that notify you the minute your glucose is too low or too high.

The more affordable CGM systems§§§13

Most covered patients pay less than $40 per month for FreeStyle Libre CGM sensorsIIIIII13.
Learn more

Ready to get started with a FREE trial?

Sign up for the MyFreeStyle program to try one of the FreeStyle Libre CGM systems — at no cost¶¶¶.
Let’s go

The FreeStyle Libre 14 day Flash Glucose Monitoring System is indicated for the management of diabetes in persons aged 18 and older.

FreeStyle Libre 2 and FreeStyle Libre 3 systems are indicated for use in people with diabetes ages 4 and older. 

Medicare coverage is available for FreeStyle Libre systems if their respective readers are used to review glucose data on some days every month. Medicare and other third party payor criteria apply.

Abbott provides this information as a courtesy, it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage or payment for our products or reimburse customers for claims that are denied by third party payors.

* FreeStyle Libre 2 and FreeStyle Libre 3 systems: Fingersticks are required if your glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol during the first 12 hours.

† FreeStyle Libre 14 day system: Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.  

‡ Data from this study was collected with the US version of the FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional real-time glucose alarms. Therefore, the study data is applicable to both products.

§ Data from this study was collected with the outside US version of FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional, real-time glucose alarms. Therefore, the study data is applicable to both products.

II Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 3 has the same features as FreeStyle Libre 14 day system with real-time glucose alarms. Therefore, the study data is applicable to both products.

¶ The FreeStyle Libre 2 app is only compatible with certain mobile devices and operating systems. Please check our compatibility guide for more information about device compatibility before using the app. Use of the FreeStyle Libre 2 app requires registration with LibreView.

# The FreeStyle Libre 3 app is only compatible with certain mobile devices and operating systems. Please check our compatibility guide for more information about device compatibility before using the app.

** The FreeStyle LibreLink app is only compatible with certain mobile devices and operating systems. Please check our compatibility guide for more information about device compatibility before using the app. Use of the FreeStyle LibreLink app requires registration with LibreView. 

†† The user's device must have internet connectivity for glucose data to automatically upload to LibreView and to transfer to connected LibreLinkUp app users.

‡‡ Glucose readings are not available during 1-hour warm-up, when sensor is too hot or too cold, when you see an error or "LO" or "HI" message, or no current glucose reading.

§§ Sensor is water-resistant in up to 1 meter (3 feet) of water. Do not immerse longer than 30 minutes.

IIII Data based on the number of claims in US for FreeStyle Libre family of personal CGMs compared to the number of claims for other personal CGM brands. Data based on the number of patients assigned to each manufacturer based on last filled prescription in US Retail Pharmacy and DME.

¶¶ Based on prescription claims for commercially insured patients starting on the FreeStyle Libre personal CGM systems compared to competitor CGMs. Does not include Medicare, Medicaid, uninsured, and other federal or state healthcare program patients. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.

## The FreeStyle Libre 3 app is designed to facilitate data sharing between patients and their healthcare providers and caregivers.

*** The LibreView data management software is intended for use by both patients and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis and evaluation of historical glucose meter data to support effective diabetes management. The LibreView software is not intended to provide treatment decisions or to be used as a substitute for professional healthcare advice.

††† Notifications will only be received when alarms are turned on and the sensor is within 20 feet unobstructed of the reading device. You must enable the appropriate settings on your smartphone to receive alarms and alerts, see the FreeStyle Libre 2 User’s Manual for more information.

‡‡‡ Notifications will only be received when alarms are turned on and the sensor is within 33 feet unobstructed of the reading device. You must enable the appropriate settings on your smartphone to receive alarms and alerts, see the FreeStyle Libre 3 User’s Manual for more information.

§§§ Based on a comparison of list prices of the FreeStyle Libre personal CGM systems versus competitors’ CGM systems, assuming annual use of one receiver (or equivalent hardware) and quantity of transmitters and/or sensors according to use life. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.

IIIIII Based on prescription claims for commercially insured patients using the FreeStyle Libre personal CGM systems. Does not include Medicare, Medicaid, uninsured, and other federal or state healthcare program patients. The actual amount a patient pays may vary. The FreeStyle Libre systems requires a prescription.

¶¶¶ or ♢ Eligible patients will receive one (1) FreeStyle Libre 2 sensor or (1) FreeStyle Libre 3 sensor for users with a compatible mobile phone operating system at $0 copay. The expiration date of the voucher is 60 days from the issue date. This program is available for patients with Type 1, Type 2, or gestational diabetes. Patients ages 18 and older are eligible to sign up and receive an offer for the (1) FreeStyle Libre 2 sensor or (1) FreeStyle Libre 3 sensor. Patients ages 4-17 are eligible to receive an offer for the (1) FreeStyle Libre 2 sensor or (1) FreeStyle Libre 3 sensor through their parent or guardian. This offer is void where prohibited by law. Abbott may modify or rescind this offer at any time without notice. The discounts are not available to beneficiaries of Kaiser Permanente, Medicare, Medicaid or other federal or state healthcare programs, residents of Massachusetts, or US territories (other than Puerto Rico). The free (1) FreeStyle Libre 2 sensor or (1) FreeStyle Libre 3 sensor is provided as a sample and is limited to one sample per eligible person per product identification number. The FreeStyle Libre 2 sensor or FreeStyle Libre 3 sensor cannot be re-sold, traded nor submitted to any third-party payer for reimbursement and is not provided as any inducement for future purchases. The free sample card is not health insurance.

References: 1. FreeStyle Libre 2 User's Manual. 2. FreeStyle Libre 3 User’s Manual. 3. FreeStyle Libre 14 day User’s Manual. 4. Unger, Jeff, Pamela Kushner, and John E. Anderson. "Practical guidance for using the FreeStyle Libre flash continuous glucose monitoring in primary care." Postgraduate Medicine 132, no 4. (2020): 305-313. https://doi.org/10.1080/00325481.2020.1744393. 5. Haak, Thomas, et al. “Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-treated Type 2 Diabetes: a Multicentre, Open-label Randomised Controlled Trial.” Diabetes Therapy 8, no. 1 (2017): 55-73. https://doi.org/10.1007/s13300-016-0223-6. 6. Bolinder, Jan, et al. "Novel glucose-sensing Technology and Hypoglycaemia in Type 1 Diabetes: a Multicentre, Non-masked, Randomised Controlled Trial." The Lancet 388, no. 10057 (2016): 2254-2263. https://doi.org/10.1016/S0140-6736(16)31535-5. 7. Campbell, Fiona M., et al. "Outcomes of Using Flash Glucose Monitoring technology by Children and young people with Type 1 Diabetes in a Single Arm Study." Pediatric Diabetes 19, no. 7 (2018): 1294-1301. https://doi.org/10.1111/pedi.12735. 8. Evans, Mark, et al. "The Impact of Flash Glucose Monitoring on Glycaemic Control as Measured by HbA1c: a Meta-analysis of Clinical Trials and Real-world Observational Studies." Diabetes Therapy 11, no. 1 (2020): 83-95. https://doi.org/10.1007/s13300-019-00720-0. 9. Kroeger, Jens, Peter Fasching, and Helene Hanaire. "Three European Retrospective Real-World Chart Review Studies to Determine the Effectiveness of Flash Glucose Monitoring on HbA1c in Adults with Type 2 Diabetes." Diabetes Therapy 11, no. 1 (2020): 279-291. https://doi.org/10.1007/s13300-019-00741-9. 10. Dunn, Timothy C., et al. "Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycemic measures: A European analysis of over 60 million glucose tests." Diabetes Research and Clinical Practice 137, no. 37 (2018): 37-46. https://doi.org/10.1016/j.diabres.2017.12.015. 11. Yaron, Marianna, et al. "Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes." Diabetes Care 42, no. 7 (2019): 1178-1184. https://doi.org/10.2337/dc18-0166. 12. Bolinder, Jan, et al. "Comparison of Flash Glucose Monitoring Usage Patterns and Glycaemic Outcomes in the Real-World with Those Observed in a Randomized Controlled Trial." Diabetes Technology & Therapeutics 20, no. S1 (2018). https://doi.org/10.1089/dia.2018.2525.abstracts. 13. Data on File. Abbott Diabetes Care.

ADC-06051 v9.0